ATE320479T1 - Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen - Google Patents

Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen

Info

Publication number: ATE320479T1
Authority: AT; Austria
Prior art keywords: receptor; cells; stimulate; development; gene
Prior art date: 1996-01-23

Application number

AT97903840T

Other languages

English (en)

Inventor

H Ralph Snodgrass

Joseph Cioffi

Thomas J Zupancic

Alan W Shafer

Adel A Mikhail

Bruce A Barut

Original Assignee

Indevus Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-23

Filing date

1997-01-21

Publication date

2006-04-15

1996-03-20 Priority claimed from US08/618,957 external-priority patent/US6355237B1/en

1997-01-21 Application filed by Indevus Pharmaceuticals Inc filed Critical Indevus Pharmaceuticals Inc

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE320479T1 publication Critical patent/ATE320479T1/de

Links

238000000034 method Methods 0.000 title abstract 2
108090000623 proteins and genes Proteins 0.000 title 2
102000016267 Leptin Human genes 0.000 abstract 3
108010092277 Leptin Proteins 0.000 abstract 3
210000003958 hematopoietic stem cell Anatomy 0.000 abstract 3
210000002889 endothelial cell Anatomy 0.000 abstract 2
230000003394 haemopoietic effect Effects 0.000 abstract 2
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 2
229940039781 leptin Drugs 0.000 abstract 2
210000004958 brain cell Anatomy 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000007774 longterm Effects 0.000 abstract 1
230000002629 repopulating effect Effects 0.000 abstract 1
210000000130 stem cell Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/355—Leptin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Developmental Biology & Embryology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Dermatology (AREA)

AT97903840T 1996-01-23 1997-01-21 Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen ATE320479T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US58991596A	1996-01-23	1996-01-23
US08/618,957 US6355237B1 (en)	1994-09-14	1996-03-20	Methods for using the obese gene and its gene product to stimulate hematopoietic development
US71329696A	1996-09-13	1996-09-13

Publications (1)

Publication Number	Publication Date
ATE320479T1 true ATE320479T1 (de)	2006-04-15

Family

ID=27416556

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97903840T ATE320479T1 (de)	1996-01-23	1997-01-21	Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen

Country Status (10)

Country	Link
EP (2)	EP1731164A1 (de)
JP (2)	JP4018142B2 (de)
AT (1)	ATE320479T1 (de)
AU (1)	AU731685C (de)
CA (1)	CA2244693A1 (de)
DE (1)	DE69735477T2 (de)
DK (1)	DK0892849T3 (de)
ES (1)	ES2260784T3 (de)
PT (1)	PT892849E (de)
WO (1)	WO1997027286A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6001968A (en)	1994-08-17	1999-12-14	The Rockefeller University	OB polypeptides, modified forms and compositions
AU1526297A (en) *	1996-01-04	1997-08-01	Amgen, Inc.	Ob protein receptor and related compositions and methods
US7074397B1 (en)	1996-01-08	2006-07-11	Genentech, Inc.	Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en)	1996-01-08	2003-04-01	Genentech, Inc.	Leptin receptor having a WSX motif
US20050019325A1 (en)	1996-01-08	2005-01-27	Carter Paul J.	WSX receptor agonist antibodies
IL120733A0 (en) *	1997-04-29	1997-08-14	Yeda Res & Dev	Leptin as an inhibitor of cell proliferation
FR2767136B1 (fr) *	1997-08-06	2004-08-27	Genset Sa	Recepteur complexe lsr, activite, clonage, et applications au diagnostic, a la prevention et/ou au traitement de l'obesite et des risques ou complications associes
FR2767135B1 (fr)	1997-08-06	2002-07-12	Genset Sa	Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
WO1999059614A1 (en) *	1998-05-20	1999-11-25	Yale University	Modulation of angiogenesis and wound healing
US7208572B2 (en)	1998-08-21	2007-04-24	Albany Medical College	Leptin-related peptides
US6777388B1 (en)	1998-08-21	2004-08-17	Clf Medical Technology Acceleration Program, Inc.	Leptin-related peptides
WO2000012683A2 (en) *	1998-08-31	2000-03-09	New York University	Stem cells bearing an fgf receptor on the cell surface
WO2000026363A1 (en)	1998-11-04	2000-05-11	Genset	GENOMIC AND COMPLETE cDNA SEQUENCES OF HUMAN ADIPOCYTE-SPECIFIC APM1 AND BIALLELIC MARKERS THEREOF
ATE427362T1 (de)	1999-02-10	2009-04-15	Serono Genetics Inst Sa	Polymorphe marker des lsr-gens
US20050272652A1 (en)	1999-03-29	2005-12-08	Gault Victor A	Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
IL132312A0 (en) *	1999-09-05	2001-03-19	Yeda Res & Dev	Use of leptin in inhibition of endothelial cell proliferation
US6989367B2 (en)	2000-01-14	2006-01-24	Genset S.A.	OBG3 globular head and uses thereof
US20020058617A1 (en)	2000-01-14	2002-05-16	Joachim Fruebis	OBG3 globular head and uses thereof for decreasing body mass
US7338787B2 (en)	2000-01-14	2008-03-04	Serono Genetics Institute S.A.	Nucleic acids encoding OBG3 globular head and uses thereof
US6566332B2 (en)	2000-01-14	2003-05-20	Genset S.A.	OBG3 globular head and uses thereof for decreasing body mass
CN1961000B (zh)	2004-02-11	2011-05-04	安米林药品公司	具有可选择特性的杂合多肽
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
MX2007009760A (es)	2005-02-11	2007-11-07	Amylin Pharmaceuticals Inc	Polipeptidos del analogo e hibrido del peptido inhibidor gastrico con propiedades seleccionables.
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
BRPI0614649A2 (pt)	2005-08-11	2011-04-12	Amylin Pharmaceuticals Inc	polipeptìdeos hìbridos com propriedades selecionáveis
EP1922336B1 (de)	2005-08-11	2012-11-21	Amylin Pharmaceuticals, LLC	Hybridpolypeptide mit auswählbaren eigenschaften
US8497240B2 (en)	2006-08-17	2013-07-30	Amylin Pharmaceuticals, Llc	DPP-IV resistant GIP hybrid polypeptides with selectable properties
TWI824372B (zh)	2015-10-12	2023-12-01	美商再生元醫藥公司	活化瘦素受體的抗原結合蛋白
JP7042816B2 (ja)	2016-11-08	2022-03-28	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	レプチン受容体をアンタゴナイズする抗原結合性タンパク質
US11834500B2 (en)	2017-12-18	2023-12-05	Regeneron Pharmaceuticals, Inc.	Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
AU2019249273A1 (en)	2018-04-06	2020-10-15	Regeneron Pharmaceuticals, Inc.	Methods of treatment using a leptin receptor agonist antibody
WO2020023621A1 (en) *	2018-07-24	2020-01-30	Puneeth Iyengar	Improved weight loss therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5643748A (en) *	1994-09-14	1997-07-01	Progenitor, Inc.	HU-B1.219, a novel human hematopoietin receptor

1997
- 1997-01-21 EP EP06004170A patent/EP1731164A1/de not_active Withdrawn
- 1997-01-21 ES ES97903840T patent/ES2260784T3/es not_active Expired - Lifetime
- 1997-01-21 AU AU18311/97A patent/AU731685C/en not_active Ceased
- 1997-01-21 AT AT97903840T patent/ATE320479T1/de not_active IP Right Cessation
- 1997-01-21 DE DE69735477T patent/DE69735477T2/de not_active Expired - Fee Related
- 1997-01-21 JP JP52692197A patent/JP4018142B2/ja not_active Expired - Fee Related
- 1997-01-21 EP EP97903840A patent/EP0892849B1/de not_active Expired - Lifetime
- 1997-01-21 DK DK97903840T patent/DK0892849T3/da active
- 1997-01-21 PT PT97903840T patent/PT892849E/pt unknown
- 1997-01-21 WO PCT/US1997/000767 patent/WO1997027286A1/en active IP Right Grant
- 1997-01-21 CA CA002244693A patent/CA2244693A1/en not_active Abandoned
2006
- 2006-12-28 JP JP2006355150A patent/JP2007163502A/ja active Pending

Also Published As

Publication number	Publication date
JP2001510982A (ja)	2001-08-07
EP0892849A4 (de)	2004-08-25
EP1731164A1 (de)	2006-12-13
DE69735477T2 (de)	2006-11-30
JP4018142B2 (ja)	2007-12-05
AU731685C (en)	2002-08-22
EP0892849B1 (de)	2006-03-15
CA2244693A1 (en)	1997-07-31
EP0892849A1 (de)	1999-01-27
PT892849E (pt)	2006-08-31
ES2260784T3 (es)	2006-11-01
WO1997027286A1 (en)	1997-07-31
AU1831197A (en)	1997-08-20
AU731685B2 (en)	2001-04-05
DK0892849T3 (da)	2006-07-24
DE69735477D1 (de)	2006-05-11
JP2007163502A (ja)	2007-06-28

Legal Events

Date

Code

Title

Description

2007-02-15

UEP

Publication of translation of european patent specification

Ref document number: 0892849

Country of ref document: EP

2008-10-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE320479T1 (de)	2006-04-15	Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen
DE59912118D1 (de)	2005-07-07	Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen
ATE264916T1 (de)	2004-05-15	Dns-konstrukten zur aktivierung und veränderung der expression von endogenen genen
ATE323756T1 (de)	2006-05-15	Natürliche killerzelllinien und verfahren zu ihrer verwendung
ATE286126T1 (de)	2005-01-15	Glialmitogene faktoren, ihre herstellung und verwendung
DE60334995D1 (de)	2010-12-30	Verfahren zur herstellung von amorphen und keramischen stoffen mittels schmelzspinnen
DE68926735D1 (de)	1996-08-01	Verwendung von spezifischen Eigenschaften der Tierallergene und Verfahren zu ihrer Herstellung
DE69725861D1 (de)	2003-12-04	Katalytische nukleinsäuren und deren medizinische verwendung
DE69717519D1 (de)	2003-01-16	Verfahren zur Herstellung von biologischem Implantationsmaterial
DE69126762D1 (de)	1997-08-14	Biologisches Verfahren zur Herstellung von Alpha-Hydroxyamid und Alpha-Hydroxysäure
ATE172493T1 (de)	1998-11-15	Rekombinante dns-mittel und verfahren
ATE377072T1 (de)	2007-11-15	Neues gen für eine aminosäure-deacetylase mit spezifität für n-acetyl-l-phosphinothricin, ihre isolierung und verwendung
WO2002070729A3 (en)	2004-01-22	Improved skin substitutes and uses thereof
DE69033068D1 (de)	1999-05-27	Verfahren zur Herstellung von Methacrolein und Methacrylsäure
NO308310B1 (no)	2000-08-28	Hovedsakelig rent KGF protein og dets anvendelse
DE60002793D1 (de)	2003-06-26	Verfahren zur Herstellung von Acrolein und Acrylsäure
ATE88500T1 (de)	1993-05-15	Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
DE60043309D1 (de)	2009-12-24	Verfahren zur herstellung und dosierung von fluffzellstoff
DE69026024D1 (de)	1996-04-25	Künstlicher Träger zur Immobilisierung von biologischen Proteinen und Verfahren zu seiner Herstellung
ATE330003T1 (de)	2006-07-15	Rekombinanter stabiler zellklon, seine herstellung und verwendung
Yuan et al.	2022	New perspective of skeletal stem cells
DE68919282D1 (de)	1994-12-15	Verfahren zur Herstellung von Cephalosporin und Zwischenverbindungen.
ATE279524T1 (de)	2004-10-15	Künstliche matrix-anheftungsregion zur erhöhung der expression von in pflanzen eingeführten genen
DE60038565D1 (de)	2008-05-21	Verfahren zur herstellung von ubiquinon-10
DE3855634D1 (de)	1996-12-05	Innerhalb des alpha-Locus gelegenes T-Zell-Rezeptor-Gen und DNA-Konstruktionen